Incyte Enters A Data-Rich Year On Path To Portfolio Diversification

Myelofibrosis, Dermatology, Oncology Readouts Ahead

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Incyte’s Jakafi-dominated portfolio gained Opzelura as a second source of significant revenue in 2021. While further diversification has been limited, new and existing R&D assets may deliver upside in 2024.

Science Research as a Concept for Presentation
Incyte anticipates many trial readouts and other R&D milestones in 2024 • Source: Shutterstock

Incyte Corporation’s oral JAK1/2 inhibitor Jakafi (ruxolitinib) has grown to dominate the myelofibrosis market since its approval in 2011. For many years, it was the company’s only commercial asset, and it remains Incyte’s top seller by a wide margin, but it is facing loss of exclusivity (LOE) in 2028. However, while it is under pressure to diversify its revenue base through new products, the company expects to achieve milestones for multiple assets in 2024 that could reach the market ahead of the Jakafi LOE.

Key Takeaways

  • Incyte will have several clinical trials readouts and other milestones in 2024 as the company seeks to diversify beyond Jakafi ahead of the drug’s loss of exclusivity in 2028.

Wilmington, DE-based Incyte’s pipeline is fueled by in-house research and development as well as business development activity, a strategy important...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category